Being told you have cancer is like a dark cloud over your life. It’s tough, no matter the type of cancer. Every day feels ...

RT-NBTXR3 followed by anti-PD-1 demonstrated favorable safety profile, disease control and tumor response in patients both naïve and resistant to anti-PD-1, suggesting that NBTXR3 may prime the immune ...

Merck MRK announced that a phase study evaluating its Daiichi Sankyo-partnered HER3-directed DXd antibody drug conjugate (ADC ...

But sex health assessments are not yet part of oncological clinical practice, despite studies showing that infertility and ...

The research team has already found that preserving lymph nodes during treatment initiation helps the body's immune system ...

ORRs of 54.8% and 50.0% achieved in locally advanced and metastatic cSCC, with median follow-up durations of 24.1 and 29.3 months, respectively. Results demonstrate a deepening of response over time, ...

Telehealth respiratory group Respiri says a sales deal with a US group will help the firm achieve cash-flow breakeven status ...

Study Meets Overall Response Rate Primary Endpoint, Encouraging Secondary Endpoint Progression-Free Survival Data in Squamous Cell Carcinoma ...

Immune checkpoint inhibitors are the superheroes of cancer therapy. | Immune checkpoint inhibitors are the superheroes of ...

Jonathan Riess, MD, MS, director of thoracic medicine at UC Davis Health, gave insight into the rationale and efficacy data for combining cancer vaccine IO102-IO103 with pembrolizumab in advanced ...

A study presented at the ESMO Congress shed light on an ADC directed against an immune checkpoint in PD-L1-expressing solid ...